dofequidar has been researched along with Stomach Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, H; Baba, M; Fukazawa, N; Naito, M; Nakanishi, O; Saito, A; Sato, S; Sato, W; Suzuki, T; Tsuruo, T; Yamashita, T | 1 |
| Aizawa, K; Fukuda, M; Ikeda, K; Kimura, Y; Kohno, S; Mizuta, Y; Nakamura, T; Noguchi, Y; Oka, M; Soda, H; Terashi, K; Tsuruo, T | 1 |
2 other study(ies) available for dofequidar and Stomach Neoplasms
| Article | Year |
|---|---|
Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Colonic Neoplasms; Colorectal Neoplasms; Doxorubicin; Drug Resistance, Multiple; Drug Synergism; Female; Humans; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Nude; Quinolines; Stomach Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured; Vincristine | 1997 |
Direct interaction between a quinoline derivative, MS-209, and multidrug resistance protein (MRP) in human gastric cancer cells.
Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Doxorubicin; Drug Resistance, Multiple; Etoposide; Fluoresceins; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Leukotriene C4; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Probenecid; Quinolines; RNA, Messenger; Stomach Neoplasms; Tumor Cells, Cultured; Vincristine | 1999 |